These trials completed more than 12 months ago and should have reported results. Some have, some have not.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Ongoing 2004-000722-69 A PHASE II, RANDOMIZED STUDY OF CARBOPLATIN-GEMCITABINE PLUS CARBOPLATIN-PACLITAXEL VERSUS CARBOPLATIN-PACLITAXEL IN PLATINUM-SENSITIVE PATIENTS WITH RECURRENT OVARIAN CARCINOMA, PRIMARY PERITONEAL CA... not-yet-due
Ongoing 2005-002495-15 "Estudio exploratorio fase II para evaluar la eficacia y seguridad de topotecan semanal en el tratamiento de cáncer de cérvix persistente o recidivante tras fracaso de tratamiento de primera línea con... not-yet-due
Listed as ongoing, but also has a completion date and reported results 2005-003929-22 Estudio aleatorizado del “Gynaecologic Cancer InterGroup”, de dos grupos, multicéntrico para añadir bevacizumab a la quimioterapia estándar (carboplatino y paclitaxel) en pacientes que sufren cáncer e... 2013-06-28 bad-data
Completed, report not yet due 2007-001346-41 A double-blind, placebo-controlled, three arm randomised multi-centre Gynaecologic Cancer InterGroup trial of AZD2171, in combination with platinum-based chemotherapy and as a single agent maintenance... 2019-08-30 not-yet-due
Not reported 2009-012859-21 A PHASE II/III STUDY OF INTRAPERITONEAL (IP) PLUS INTRAVENOUS (IV) CHEMOTHERAPY VERSUS IV CARBOPLATIN PLUS PACLITAXEL IN PATIENTS WITH EPITHELIAL OVARIAN CANCER OPTIMALLY DEBULKED AT SURGERY FOLLOWING... 2016-07-11 due-trials
Completed, but no date 2010-018478-19 Ensayo fase II para evaluar la eficacia y seguridad de catumaxomab como tratamiento de consolidación en pacientes con un cáncer epitelial de ovario en una segunda o tercera remisión completa bad-data
Ongoing 2010-020439-38 Ensayo clínico fase II no controlado, multicéntrico y prospectivo para determinar el beneficio clínico y toxicidad de Pazopanib, inhibidor multidiana de receptores con actividad tirosin-quinasa (VEGFR... not-yet-due
Ongoing 2010-023525-38 ENSAYO EN FASE III ALEATORIZADO DE CISPLATINO MÁS PACLITAXEL CON Y SIN BEVACIZUMAB FRENTE AL DOBLETE SIN PLATINO, TOPOTECAN MÁS PACLITAXEL, CON Y SIN BEVACIZUMAB, EN CARCINOMA DE CÉRVIX EN ESTADIO IVB... not-yet-due
Not reported Terminated 2012-003883-31 A randomized phase II multi-centric open label clinical trial to determine the efficacy and toxicity of preoperative chemotherapy with or without bevacizumab in patients with advanced Ovarian Cancer. 2019-05-17 due-trials
Ongoing 2015-004472-30 Randomized phase III trial on Trabectedin (ET-743) vs clinician's choice chemotherapy in recurrent ovarian, primary peritoneal or fallopian tube cancers of BRCA mutated or BRCAness phenotype patients ... not-yet-due
Other 2016-004850-14 Multicentric Single Arm Phase II Clinical Trial, to Evaluate Safety and Efficacy of the Combination of Olaparib and PLD for Platinum Resistant Ovarian Primary Peritoneal Carcinoma, and Fallopian Tube ... not-yet-due
Ongoing 2017-003183-13 Phase-II study of olaparib as maintenance therapy after response to trabectedinpegylated liposomal doxorubicin in recurrent ovarian carcinoma. not-yet-due
Ongoing 2018-000366-11 A phase III randomized, double-blinded trial of platinum-based chemotherapy with or without atezolizumab followed by niraparib maintenance with or without atezolizumab in patients with recurrent ovari... not-yet-due
Ongoing 2018-000367-83 A Randomized Phase III Trial of Platinum Chemotherapy plus Paclitaxel with Bevacizumab and Atezolizumab versus Platinum Chemotherapy plus Paclitaxel and Bevacizumab in Metastatic (stage IVB), Persiste... not-yet-due
Ongoing 2018-000843-14 A phase II multicenter, open-label, single arm trial of avelumab in combination with pegylated liposomal doxorubicin in recurrent/metastatic endometrial cancer not-yet-due
Ongoing 2018-002155-15 A randomized, open label, phase II trial of Anti-PD1, TSR-042, as maintenance therapy for patients with high-risk locally advanced cervical cancer after chemo-radiation not-yet-due